146 related articles for article (PubMed ID: 38647446)
1. Self-Stimulated Photodynamic Nanoreactor in Combination with CXCR4 Antagonists for Antileukemia Therapy.
Zhang Y; Chen L; Fu T; Xu A; Li K; Hao K; Lyu J; Wang Z; Kong F
ACS Appl Mater Interfaces; 2024 May; 16(17):21610-21622. PubMed ID: 38647446
[TBL] [Abstract][Full Text] [Related]
2. Improving chemotherapeutic efficiency in acute myeloid leukemia treatments by chemically synthesized peptide interfering with CXCR4/CXCL12 axis.
Li X; Guo H; Duan H; Yang Y; Meng J; Liu J; Wang C; Xu H
Sci Rep; 2015 Nov; 5():16228. PubMed ID: 26538086
[TBL] [Abstract][Full Text] [Related]
3. Targeting the leukemia microenvironment by CXCR4 inhibition overcomes resistance to kinase inhibitors and chemotherapy in AML.
Zeng Z; Shi YX; Samudio IJ; Wang RY; Ling X; Frolova O; Levis M; Rubin JB; Negrin RR; Estey EH; Konoplev S; Andreeff M; Konopleva M
Blood; 2009 Jun; 113(24):6215-24. PubMed ID: 18955566
[TBL] [Abstract][Full Text] [Related]
4. Dissecting the role of the CXCL12/CXCR4 axis in acute myeloid leukaemia.
Ladikou EE; Chevassut T; Pepper CJ; Pepper AG
Br J Haematol; 2020 Jun; 189(5):815-825. PubMed ID: 32135579
[TBL] [Abstract][Full Text] [Related]
5. Role of CXCR4 in the pathogenesis of acute myeloid leukemia.
Peled A; Tavor S
Theranostics; 2013; 3(1):34-9. PubMed ID: 23382784
[TBL] [Abstract][Full Text] [Related]
6. Dynamic chemotherapy-induced upregulation of CXCR4 expression: a mechanism of therapeutic resistance in pediatric AML.
Sison EA; McIntyre E; Magoon D; Brown P
Mol Cancer Res; 2013 Sep; 11(9):1004-16. PubMed ID: 23754844
[TBL] [Abstract][Full Text] [Related]
7. Defining the in vivo characteristics of acute myeloid leukemia cells behavior by intravital imaging.
Duarte D; Amarteifio S; Ang H; Kong IY; Ruivo N; Pruessner G; Hawkins ED; Lo Celso C
Immunol Cell Biol; 2019 Feb; 97(2):229-235. PubMed ID: 30422351
[TBL] [Abstract][Full Text] [Related]
8. CXCR4 inhibitors selectively eliminate CXCR4-expressing human acute myeloid leukemia cells in NOG mouse model.
Zhang Y; Patel S; Abdelouahab H; Wittner M; Willekens C; Shen S; Betems A; Joulin V; Opolon P; Bawa O; Pasquier F; Ito M; Fujii N; Gonin P; Solary E; Vainchenker W; Coppo P; De Botton S; Louache F
Cell Death Dis; 2012 Oct; 3(10):e396. PubMed ID: 23034331
[TBL] [Abstract][Full Text] [Related]
9. An Auristatin nanoconjugate targeting CXCR4+ leukemic cells blocks acute myeloid leukemia dissemination.
Pallarès V; Unzueta U; Falgàs A; Sánchez-García L; Serna N; Gallardo A; Morris GA; Alba-Castellón L; Álamo P; Sierra J; Villaverde A; Vázquez E; Casanova I; Mangues R
J Hematol Oncol; 2020 Apr; 13(1):36. PubMed ID: 32295630
[TBL] [Abstract][Full Text] [Related]
10. Targeting the CXCL12/CXCR4 axis in acute myeloid leukemia: from bench to bedside.
Cho BS; Kim HJ; Konopleva M
Korean J Intern Med; 2017 Mar; 32(2):248-257. PubMed ID: 28219003
[TBL] [Abstract][Full Text] [Related]
11. TGF-β-Neutralizing Antibody 1D11 Enhances Cytarabine-Induced Apoptosis in AML Cells in the Bone Marrow Microenvironment.
Tabe Y; Shi YX; Zeng Z; Jin L; Shikami M; Hatanaka Y; Miida T; Hsu FJ; Andreeff M; Konopleva M
PLoS One; 2013; 8(6):e62785. PubMed ID: 23826077
[TBL] [Abstract][Full Text] [Related]
12. CXCR4 Signaling Has a CXCL12-Independent Essential Role in Murine MLL-AF9-Driven Acute Myeloid Leukemia.
Ramakrishnan R; Peña-Martínez P; Agarwal P; Rodriguez-Zabala M; Chapellier M; Högberg C; Eriksson M; Yudovich D; Shah M; Ehinger M; Nilsson B; Larsson J; Hagström-Andersson A; Ebert BL; Bhatia R; Järås M
Cell Rep; 2020 May; 31(8):107684. PubMed ID: 32460032
[TBL] [Abstract][Full Text] [Related]
13. Antileukemia activity of the novel peptidic CXCR4 antagonist LY2510924 as monotherapy and in combination with chemotherapy.
Cho BS; Zeng Z; Mu H; Wang Z; Konoplev S; McQueen T; Protopopova M; Cortes J; Marszalek JR; Peng SB; Ma W; Davis RE; Thornton DE; Andreeff M; Konopleva M
Blood; 2015 Jul; 126(2):222-32. PubMed ID: 26031918
[TBL] [Abstract][Full Text] [Related]
14. Targeting CXCR4/SDF-1 axis by lipopolymer complexes of siRNA in acute myeloid leukemia.
Landry B; Gül-Uludağ H; Plianwong S; Kucharski C; Zak Z; Parmar MB; Kutsch O; Jiang H; Brandwein J; Uludağ H
J Control Release; 2016 Feb; 224():8-21. PubMed ID: 26742943
[TBL] [Abstract][Full Text] [Related]
15. Role of CXCL12 and CXCR4 in the pathogenesis of hematological malignancies.
Peled A; Klein S; Beider K; Burger JA; Abraham M
Cytokine; 2018 Sep; 109():11-16. PubMed ID: 29903571
[TBL] [Abstract][Full Text] [Related]
16. The CXCR4 antagonist AMD3100 impairs survival of human AML cells and induces their differentiation.
Tavor S; Eisenbach M; Jacob-Hirsch J; Golan T; Petit I; Benzion K; Kay S; Baron S; Amariglio N; Deutsch V; Naparstek E; Rechavi G
Leukemia; 2008 Dec; 22(12):2151-5158. PubMed ID: 18769446
[TBL] [Abstract][Full Text] [Related]
17. A designed peptide targeting CXCR4 displays anti-acute myelocytic leukemia activity in vitro and in vivo.
Li X; Guo H; Yang Y; Meng J; Liu J; Wang C; Xu H
Sci Rep; 2014 Oct; 4():6610. PubMed ID: 25312253
[TBL] [Abstract][Full Text] [Related]
18. [CXCR4: a new therapeutic target of the leukaemic cell? Role of the SDF-1/CXCR4 axis in acute myeloid leukaemia].
Tavernier E; Aanei C; Solly F; Flandrin-Gresta P; Campos L; Guyotat D
Bull Cancer; 2014 Jun; 101(6):593-604. PubMed ID: 24977448
[TBL] [Abstract][Full Text] [Related]
19. CXCR4 chemokine receptor signaling induces apoptosis in acute myeloid leukemia cells via regulation of the Bcl-2 family members Bcl-XL, Noxa, and Bak.
Kremer KN; Peterson KL; Schneider PA; Meng XW; Dai H; Hess AD; Smith BD; Rodriguez-Ramirez C; Karp JE; Kaufmann SH; Hedin KE
J Biol Chem; 2013 Aug; 288(32):22899-914. PubMed ID: 23798675
[TBL] [Abstract][Full Text] [Related]
20. Tissue-Nonspecific Alkaline Phosphatase Is Required for MC3T3 Osteoblast-Mediated Protection of Acute Myeloid Leukemia Cells from Apoptosis.
Sterner RM; Kremer KN; Dudakovic A; Westendorf JJ; van Wijnen AJ; Hedin KE
J Immunol; 2018 Aug; 201(3):1086-1096. PubMed ID: 29914885
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]